Eris Lifesciences Ltd · NSE:ERIS
Eris Lifesciences — Q1 FY23 Earnings Presentation
18 slides from Eris Lifesciences's earnings presentation, Aug 5, 2022
Slide 1: Stock exchange cover letter: Investor Presentation
Date: 05 August 2022 To To BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers Exchange Plaza Dalal Street Bandra Kurla Complex Mumbai- 400001 Bandra (E) Mumbai-400051 Security Code: 540596 Symbol: ERIS SUBJECT: INVESTOR PRESENTATION Dear Sir/Madam, Pursuant to the require
Slide 2: Q1 FY23 Investor Presentation
Q1 FY23 INVESTOR PRESENTATION 5th Aug 2022 1
Slide 3: Q1 FY23 – Highlights of the Quarter 1/2
Q1 FY 23 – HIGHLIGHTS OF THE QUARTER 1/2 INR mn INR mn INR mn 3,986 1,292 931 14.1% 32.4% 23.4% Op Revenue yoy growth EBITDA Ebitda margin PAT PAT margin • Zomelis Mother Brand hits a revenue run rate of Rs. 100 cr. p.a. in just 2.5 years of acquisition, representing a growth of more than 8x in mont
Slide 4: Q1 FY23 – Highlights of the Quarter 2/2
Q1 FY 23 – HIGHLIGHTS OF THE QUARTER 2/2 • Expecting stronger momentum in core cardio-metabolic business in subsequent quarters • Sharp revival of the market in Jun-July 2022 (13% growth) • After a 12-month period of slowdown (4% growth) from Jun-21 to May-22 • Successfully executing on strategic ob
Slide 5: Q1 FY23 – Entity Wise Margin Profile
Q1 FY 23 – ENTITY WISE MARGIN PROFILE Q1 FY 23 % of Ebitda Margin Entity Consol. Op Revenue YoY Gr EBITDA YoY Gr Revenue • Q1 standalone Gross Margin of 82.0% vs. 83.60% Q1 ‘23 Q1 ‘22 for FY22 – decline of 162 bps • Product mix variation in Q1 FY23 Eris (Standalone) 3,288 7.3% 1,262 3.0% 82% 38.4% 4
Slide 6: Eris ranks among the top-10 growing fastest companies in Q1 FY23
ERIS RANKS AMONG THE TOP-10 GROWING FASTEST COMPANIES IN Q1 FY23 22.7 Eris has outperformed the 19.6 IPM by 600 bps in 17.7 Q1 FY23 16.7 11.8 8.1 8.1 7.3 2.1 2.6 1.4 % Acute Therapy IPM MANKIND INTAS IPCA TORRENT SUN* ERIS LS GSK ZYDUS* ABBOTT* ALKEM* contribution1 46% 52% 24% 66% 26% 42% 11% 71% 51
Slide 7: Continues to outperform in cardiometabolic by a significant margin
CONTINUES TO OUTPERFORM IN CARDIOMETABOLIC BY A SIGNIFICANT MARGIN Eris grew at 8.1% in Q1 FY 23 vs. IPM growth of 2.1%; outperformed IPM in Cardio-Metabolic, CNS, Derma & Women’s Health therapies IPM Eris Cardio-Metabolic : 53% of Eris VMN : 16% of Eris 21.1 61.2 18.7 14.9 46.9 12.2 13.6 11.2 5.7 5
Slide 8: Three emerging therapies (20% of revenue) growing at 25% plus p.a.
THREE EMERGING THERAPIES (20% OF REVENUE) GROWING AT 25% PLUS P.A. IPM Eris Derma: 8% of Eris CNS : 7% of Eris Women’s Health : 5% of Eris 25.8 38.3 39.2 49.3 30.0 38.1 25.5 25.3 28.0 24.1 13.1 15.0 16.5 15.3 11.1 12.2 10.6 7.7 3.7 1.8 2.4 0.4 Q1FY23 Q1FY22 Q2FY22 Q3FY22 Q4FY22 Q1FY23 Q1FY22 Q2FY22
Slide 9: Eris maintains high prescription ranking among doctor specialties
ERIS MAINTAINS HIGH PRESCRIPTION RANKING AMONG DOCTOR SPECIALTIES Eris Prescription Ranking* among Doctor Specialties 3 4 4 DIABETOLOGISTS # CARDIOLOGISTS NEUROLOGISTS 5 CONSULTING 7 8 GASTROENTEROLOGISTS PHYSICIANS DERMATOLOGISTS ** Source: SMSRC MAT Jun 2022 │* Rank in Represented Market excluding
Slide 10: Power brands continue to have leading presence in core therapies (1/2)
POWER BRANDS CONTINUE TO HAVE LEADING PRESENCE IN CORE THERAPIES (1/2) Therapy wide presence in Oral Diabetes Care with power brands holding high ranks in Newer-generation fast-growing molecules Sulfonylurea rank 6 in the ≈4,800 cr Glimepiride and combinations market Glimisave MV rank 2 in Glimepiri
Slide 11: Power brands continue to have leading presence in core therapies (2/2)
POWER BRANDS CONTINUE TO HAVE LEADING PRESENCE IN CORE THERAPIES (2/2) High rank in Anti-Hypertensives: the largest segment of Cardiac Care rank 5 in the ≈3,900 cr Telmisartan and combinations market Eritel CH rank 5 in Telmisartan + Chlorthalidone market Eritel LN rank 2 in Telmisartan + Cilnidipin
Slide 12: Q1 FY23 - Standalone Income Statement
Q1 FY 23 - STANDALONE INCOME STATEMENT Standalone Q1 FY 23 Q1 FY 23 Q1 FY 22 INR Millions yoy GR Sale of Products 3,220 3,003 7.2% • Operating Revenue grew by 7.3% yoy in Q1 FY 23 amid continued Other Operating Income 67 60 13.0% Revenue from Operations 3,288 3,063 7.3% market slowdown in Apr-May 20
Slide 13: Q1 FY23 - Consolidated Income Statement
Q1 FY 23 - CONSOLIDATED INCOME STATEMENT Consolidated Q1 FY 23 Q1 FY 23 Q1 FY 22 INR Millions yoy GR Sale of Products 3,921 3,437 14.1% • Consolidated Operating Revenue grew by 14.1% yoy in Other Operating Income 65 56 16.3% Revenue from Operations 3,986 3,493 14.1% Q1 FY 23. Growth adjusted for Cov
Slide 14: Eris continues to execute on growth drivers (1/2)
ERIS CONTINUES TO EXECUTE ON GROWTH DRIVERS (1/2) Expansion of power- • Our business model of building strong and sustainable brands has enabled us to significantly 1 brands’ franchise outperform the market • There has been a clear shift in prescriber preference towards established brands over the l
Slide 15: Eris continues to execute on growth drivers (2/2)
ERIS CONTINUES TO EXECUTE ON GROWTH DRIVERS (2/2) Expansion of physician • We continue to make good progress in expanding our coverage of Specialists and 3 coverage Consulting Physicians in line with our expectations • We have expanded our field-force by ~ 150 in the recent past • We continue to inv
Slide 16: Shareholder Profile
SHAREHOLDER PROFILE Shareholding of Promoters and Top 15 Institutional Investors As on As on As on Name of Shareholder 30-Jun-22 31-Mar-22 31-Dec-21 Others 667* 689* 760* FPIs 0.36% 15.35% Promoters 52.30% 52.66% 52.66% 1 Chrys Capital (Emerald Investment Limited) 7.58% 5.50% 5.50% 2 UTI Mutual Fund
Slide 17: Safe Harbor Statement
SAFE HARBOR STATEMENT This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward- looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and the underlying assumptions
Slide 18: Thank You
THANK YOU KRUTI RAVAL INVESTOR RELATIONS kruti@erislifesciences.com 17